P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma

• Conrad-Amadeus Voltin,
• Stefanie Kreissl,
• Helen Kaul,
• Ina Bühnen,
• Jasmin Mettler,
• Thomas Pabst,
• Dennis A. Eichenauer,
• Michael Fuchs,
• Volker Diehl,
• Markus Dietlein,
• Andreas Engert,
• Peter Borchmann,
• Carsten Kobe

Affiliations

Conrad-Amadeus Voltin

1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Stefanie Kreissl

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Helen Kaul

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Ina Bühnen

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Jasmin Mettler

1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Thomas Pabst

3 Department of Medical Oncology, Bern University Hospital, University of Bern, Bern, Switzerland

Dennis A. Eichenauer

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Michael Fuchs

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Volker Diehl

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Markus Dietlein

1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Andreas Engert

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Peter Borchmann

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Centre for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Carsten Kobe

1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany